CU Lymphoma Program
@CULymphoma
The official account for the @CUMedicalSchool @CUAnschutz Lymphoma Program. #lymsm
Our @CUHematology website features all of our open B- and T-cell lymphoma and cellular therapy clinical trials, by Drs. @mana1981, @BradHaverkos, @StevenBairMD and @majorajay. #lymsm #clinicaltrials medschool.cuanschutz.edu/hematology/all…
Our @CULymphoma faculty Dr. @majorajay contributed to a large multicenter study of bispecific antibody therapy outcomes, published @BloodPortfolio. #lymsm #tcellrx cc @CUAnschutz @CUCancerCenter @CUHematology
A huge congratulations to @MedicineCU resident physician Dr. @vpizzuti44 on his @ASH_hematology HONORS Award with mentor and @CULymphoma lead Dr. @mana1981! #lymsm cc @CUMedicalSchool @CUAnschutz @CUInternalMed
I am happy to announce I was selected by @ASH_Hematology to receive the ASH HONORS Award! Excited for this project studying PET/CT radiomics in DLBCL. Grateful to @mana1981 for her mentorship and ASH for the support! #ASHAwards #Fight4Hematology @CULymphoma @CUDeptMedicine
Congratulations to our @CULymphoma lead Dr. @mana1981 on her first-author publication in @JCO_ASCO about the 3-year follow-up of TRANSFORM! ascopubs.org/doi/10.1200/JC… #lymsm #tcellrx
Congratulations to all the CUBIC investigators, led by Dr. @drsairahahmed! We are proud to contribute to this growing bispecific registry at @CULymphoma. cc @mana1981 #18ICML #lymsm
@DanilovLab presenting #CUBIC (collaborative US bispecific consortium) data - RWE outcomes of tiNHL with T-cell engagers #ICML2025 @JenCrombieMD @majorajay @ChrisRFlowersMD @MDAndersonNews
If you want to hear more from the authors of the first set of commission manuscripts, our @TheLancetHaem podcast is now online! buzzsprout.com/1564352/episod… ft. @GitaThanaMD @BiostatGirl @BroeckelmannPJ #EHA2025
Great to join @BroeckelmannPJ presenting data from our recent @TheLancetHaem commission on adverse events, starting with the paper by @majorajay @BiostatGirl on advancing AE measurement #EHA2025 @GitaThanaMD
Next @BroeckelmannPJ highlighting these very nice tables from @majorajay @BiostatGirl on new dashboards for better capturing AEs #EHA2025 #EHA25 @TheLancetHaem @young_eha @EHA_Hematology
Great to join @BroeckelmannPJ presenting data from our recent @TheLancetHaem commission on adverse events, starting with the paper by @majorajay @BiostatGirl on advancing AE measurement #EHA2025 @GitaThanaMD
For those missing the #EHA2025 fun, a #podcast discussing the @TheLancetHaem Commission topic of better adverse event assessment was just posted! buzzsprout.com/1564352/episod… @BroeckelmannPJ @majorajay, @GitaThanaMD (also features Vishal Bhatnagar & Lan-Lan Smith not on X)
Great to join @BroeckelmannPJ presenting data from our recent @TheLancetHaem commission on adverse events, starting with the paper by @majorajay @BiostatGirl on advancing AE measurement #EHA2025 @GitaThanaMD
Navigating CART for Lymphoma in 2025 - great session at #EHA2025 with @mana1981 @KRejeski and the OG Prof Zinzani #CART #lymsm
You made my day James !!! Thank you !!!
On a personal note, my son wrote a heartfelt thank you to my husband’s amazing med onc, Manali Kamdar @mana1981 to celebrate 5 years NED from DLBCL. She met us at a difficult time right before our son’s birth and guided us expertly and with immense compassion ❤️ @CUCancerCenter
Modern therapeutics call for a modernized approach to measuring, analyzing and reporting adverse events! Read our @TheLancetHaem paper for the Commission on Adverse Event Reporting, with @BiostatGirl & @GitaThanaMD thelancet.com/journals/lanha… #clinicaltrial #dataviz
Congratulations to our @CULymphoma faculty Dr. @majorajay on publication of the first installation of the @TheLancetHaem Commission on Adverse Event Reporting! thelancet.com/series-do/adve… cc @CUCancerCenter @CUDeptMedicine @CUAnschutz @CUMedicalSchool
Announcing the first paper of @TheLancetHaem Commission on Adverse Events, with @BiostatGirl & @GitaThanaMD. We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination. sciencedirect.com/science/articl… Thread ⬇️ 🧵
Excited to share our latest paper calling for a modernized approach to AE measurement, analysis, visualization, & reporting led by @majorajay! 📊🧬#hematology #ClinicalTrials #lymsm #dataviz authors.elsevier.com/c/1lAZ98MsWYNW…
Happy #NationalHospitalWeek 🥳 Let's take a moment to celebrate the incredible individuals who make our hospitals a place of healing, hope, and compassion. This week is for you! 👏
Elated to be joining the @ASH_hematology Clinical Research Training Institute (CRTI) in 2025! Eager to work on our research program utilizing PROs to improve treatment decision-making in indolent lymphomas. Deeply grateful to my mentors Drs. @hawkeyestudts & @mana1981. #lymsm
Come join us this morning at #XGM2025 to learn about integration of eSyM remote symptom monitoring in patients with cancer, including our experience @CUCancerCenter @CULymphoma. #onctwitter
Checking in at #XGM2025! Many thanks for the invitation to speak on our implementation of the eSyM electronic symptom monitoring platform @CUCancerCenter as part of the PCORI-funded OncoPRO initiative. #onctwitter
We are seeking patients with relapsed or refractory FL or DLBCL for a compensated study about experiences with bispecific antibody therapies. To my #lymsm & #onctwitter colleagues: please share the attached flyer with your networks. Thank you! #tcellrx
We love to see this collaboration! imPROve is one of many Work in Progress (WIP) groups hosted by ACCORDS to facilitate meeting and collaboration around specific topic areas in health services research. Learn more: medschool.cuanschutz.edu/accords/resear…
Our imPROve Working Group meeting today to discuss a new patient-reported outcomes (PRO) instrument by @CUDeptSurg. imPROve is a think tank of PRO methodologists across @CUAnschutz who can help develop your studies; contact us if interested in presenting: medschool.cuanschutz.edu/accords/resear…
Our @CULymphoma faculty Dr. @majorajay contributed to a multicenter study of venetoclax in relapsed/refractory Waldenstrom macroglobulinemia, now published @BloodCancerJnl. #lymsm pmc.ncbi.nlm.nih.gov/articles/PMC12…
